In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 12, 2024), Valence8 US LP reported 40 stock positions worth $229.4 million . Its top holding was iShares MSCI USA Quality Fac (QUAL) at 26.4% of the portfolio, followed by Invesco QQQ Trust Series 1 (QQQ, 18.8% ) and iShares MSCI International Q (IQLT, 18.6% ). Compared with Q2 2024, it opened 31 new positions, added to 3 and reduced 4. The biggest buy was a new position in Jazz Pharmaceuticals (JAZZ) and the biggest sale Vanguard Mrngstr Val ETF-Aui (VTV, shares −3% ).
Location Cambridge, MA
CIK 0001943819
Portfolio Value $229.4M (Q3 2024) Holdings 40 stocks · $229.4M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q2 2024 QUAL iShares MSCI USA Quality Fac 337,472 $60.5M Add +12.1% QQQ Invesco QQQ Trust Series 1 88,149 $43.0M Add +14.9% IQLT iShares MSCI International Q 1,026,290 $42.6M Add +15.0% EFV iShares MSCI Eafe Value ETF 399,186 $23.0M No change VTV Vanguard Mrngstr Val ETF-Aui 96,630 $16.9M Reduce -3.4% XLP SS Consumer Staples Sel Sect 165,267 $13.7M Reduce -1.8% EWU iShares MSCI United Kingdom 209,344 $7.8M Reduce -3.5% EWJ iShares MSCI Japan ETF 108,634 $7.8M No change XLU St Sr Utl SL SE SPDR ETF-Usd 51,940 $4.2M Reduce -6.6% JAZZ Jazz Pharmaceuticals PLC 8,969 $999K New BMY Bristol-Myers Squibb Co. 17,785 $920K New ASND Ascendis Pharma A/S 4,585 $685K New INSM Insmed Inc. 7,865 $574K New INDV Indivior Ltd. 57,293 $564K New LLY Eli Lilly & Co. 633 $561K New ARGX Argenx SE - ADR 953 $517K New SLNO Soleno Therapeutics Inc. 9,706 $490K New KROS Keros Therapeutics Inc. 8,025 $466K New NUVL Nuvalent Inc. Class A 4,115 $421K New JANX Janux Therapeutics Inc. 7,857 $357K New CRNX Crinetics Pharmaceuticals Inc. 6,684 $342K New TYRA Tyra Biosciences Inc. 13,188 $310K New APGE Apogee Therapeutics Inc. 5,240 $308K New PCVX Vaxcyte Inc. 2,468 $282K New NTLA Intellia Therapeutics Inc. 13,020 $268K New VIR Vir Biotechnology Inc. 33,650 $252K New BPMC Blueprint Medicines Corp. 2,618 $242K New RARE Ultragenyx Pharmaceutical Inc. 4,241 $236K New ENTA Enanta Pharmaceuticals Inc. 19,939 $207K New RLAY Relay Therapeutics Inc. 26,200 $185K New ZVRA Zevra Therapeutics Inc. 21,596 $150K New ERAS Erasca Inc. 46,923 $128K New SLDB Solid Biosciences Inc. 15,728 $110K New VTGN Vistagen Therapeutics Inc. 34,376 $103K New ZURA Zura Bio Ltd. 17,495 $71K New ALEC Alector Inc. 14,708 $69K New CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC 12,045 $61K New CYPH Cypherpunk Technologies Inc. filed as LEAP THERAPEUTICS INC 18,511 $48K New NKTR Nektar Therapeutics 26,107 $34K New KEZAR LIFE SCIENCES INC 21,136 $16K New
Options reported separately and not counted above: AZN calls ($5.0M), AMGN puts ($644K), AMGN calls ($644K), SLNO calls ($631K), CRSP calls ($615K), INSM calls ($482K), NVO calls ($464K), FLNA puts ($415K), RARE calls ($383K), APLS calls ($378K), AVDL calls ($344K), VRDN calls ($298K), and 10 more.
Portfolio Sells Q2 2024 → Q3 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▲ VTV Vanguard Mrngstr Val ETF-Aui Reduce -3.4% 7.35% −1.01 XLP SS Consumer Staples Sel Sect Reduce -1.8% 5.98% −0.74 EWU iShares MSCI United Kingdom Reduce -3.5% 3.41% −0.53 XLU St Sr Utl SL SE SPDR ETF-Usd Reduce -6.6% 1.83% −0.15
Portfolio Buys Q2 2024 → Q3 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q2 2024 % Of Portfolio Change To Portfolio ▼ JAZZ Jazz Pharmaceuticals PLC New 0.44% +0.44 BMY Bristol-Myers Squibb Co. New 0.40% +0.40 IQLT iShares MSCI International Q Add +15.0% 18.56% +0.40 ASND Ascendis Pharma A/S New 0.30% +0.30 INSM Insmed Inc. New 0.25% +0.25 INDV Indivior Ltd. New 0.25% +0.25 LLY Eli Lilly & Co. New 0.24% +0.24 ARGX Argenx SE - ADR New 0.23% +0.23 SLNO Soleno Therapeutics Inc. New 0.21% +0.21 KROS Keros Therapeutics Inc. New 0.20% +0.20 NUVL Nuvalent Inc. Class A New 0.18% +0.18 JANX Janux Therapeutics Inc. New 0.16% +0.16 CRNX Crinetics Pharmaceuticals Inc. New 0.15% +0.15 TYRA Tyra Biosciences Inc. New 0.14% +0.14 APGE Apogee Therapeutics Inc. New 0.13% +0.13 PCVX Vaxcyte Inc. New 0.12% +0.12 NTLA Intellia Therapeutics Inc. New 0.12% +0.12 VIR Vir Biotechnology Inc. New 0.11% +0.11 BPMC Blueprint Medicines Corp. New 0.11% +0.11 RARE Ultragenyx Pharmaceutical Inc. New 0.10% +0.10 ENTA Enanta Pharmaceuticals Inc. New 0.09% +0.09 RLAY Relay Therapeutics Inc. New 0.08% +0.08 ZVRA Zevra Therapeutics Inc. New 0.07% +0.07 ERAS Erasca Inc. New 0.06% +0.06 SLDB Solid Biosciences Inc. New 0.05% +0.05 VTGN Vistagen Therapeutics Inc. New 0.05% +0.05 ZURA Zura Bio Ltd. New 0.03% +0.03 ALEC Alector Inc. New 0.03% +0.03 CLYM Climb Bio Inc. New 0.03% +0.03 CYPH Cypherpunk Technologies Inc. New 0.02% +0.02 NKTR Nektar Therapeutics New 0.01% +0.01 KEZAR LIFE SCIENCES INC New 0.01% +0.01 QQQ Invesco QQQ Trust Series 1 Add +14.9% 18.75% −0.40 QUAL iShares MSCI USA Quality Fac Add +12.1% 26.37% −0.42
Options Activity Q2 2024 → Q3 2024 Security Type Change vs Q2 2024 Underlying Shares Value ▼ AZN Astrazeneca PLC-Spons ADR call New 64,000 $5.0M AMGN Amgen Inc. put New 2,000 $644K AMGN Amgen Inc. call New 2,000 $644K SLNO Soleno Therapeutics Inc. call New 12,500 $631K CRSP Crispr Therapeutics AG call New 13,100 $615K INSM Insmed Inc. call New 6,600 $482K NVO Novo-Nordisk A/S-Spons ADR call New 3,900 $464K FLNA Filana Therapeutics Inc. put New 14,100 $415K RARE Ultragenyx Pharmaceutical Inc. call New 6,900 $383K APLS Apellis Pharmaceuticals Inc. call New 13,100 $378K AVDL Avadel Pharmaceuticals Ltd. call New 26,200 $344K VRDN Viridian Therapeutics Inc. call New 13,100 $298K MRNA Moderna Inc. call New 4,100 $274K CLDX Celldex Therapeutics Inc. put New 6,500 $221K APLT Applied Therapeutics Inc. call New 20,300 $173K ALT Altimmune Inc. call New 26,200 $161K ALT Altimmune Inc. put New 23,500 $144K IOVA Iovance Biotherapeutics Inc. call New 13,100 $123K JANX Janux Therapeutics Inc. put New 2,300 $104K BCRX Biocryst Pharmaceuticals Inc. call New 13,100 $100K CCCC C4 Therapeutics Inc. call New 10,500 $60K GOSS Gossamer Bio Inc. call New 20,700 $20K
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 15 $300.5M QUAL, QQQ, BIL, IQLT, XLP Q1 2026 14 $286.1M QUAL, BIL, IQLT, QQQ, EFV Q4 2025 15 $337.5M BIL, QUAL, QQQ, IQLT, EFV Q3 2025 14 $291.7M QUAL, QQQ, IQLT, BIL, EFV Q2 2025 12 $237.6M QUAL, QQQ, IQLT, EFV, VTV Q1 2025 10 $213.3M QUAL, IQLT, QQQ, EFV, VTV Q4 2024 10 $208.2M QUAL, QQQ, IQLT, EFV, VTV Q3 2024 40 $229.4M QUAL, QQQ, IQLT, EFV, VTV Q2 2024 9 $191.9M QUAL, QQQ, IQLT, EFV, VTV Q1 2024 9 $191.8M QUAL, IQLT, QQQ, EFV, VTV